Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in ...

Intersex individuals in India face challenges including non-consensual surgeries, lack of recognition, and misclassification ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation ...

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) is expected to issue its quarterly earnings data on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.82) per share and ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

such as late-onset congenital adrenal hyperplasia and Cushing's syndrome. The more recent 2003 Rotterdam consensus workshop was in response to an increasing awareness that the clinical expression ...

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock has reached a 52-week low, trading at $35.47, with InvestingPro technical indicators showing oversold conditions. The stock has declined sharply, ...

Congenital adrenal hyperplasia (CAH) is a monogenic autosomal recessive ... may delay the diagnosis leading to mismanagement and inappropriate treatment. Furthermore, we should keep in mind that the ...

High testosterone in women can cause symptoms such as unwanted facial hair, acne, irregular menstrual cycles, and hair loss. If you notice one or more of these symptoms, schedule an appointment with a ...

The number of postural symptoms was comparable and low in all treatment groups. Thus, in this clinical trial, alfuzosin was more effective than finasteride, and no additional benefit was observed ...